{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:01:31Z","timestamp":1789916491614,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.radonc.2026.111789","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:24:44Z","timestamp":1789914284000},"page":"111789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4337-7575","authenticated-orcid":false,"given":"Gustavo A.","family":"Viani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Hamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-9958","authenticated-orcid":false,"given":"Caio Viani","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio A.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo O.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111789_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.radonc.2026.111789_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e11512","article-title":"Incidence and implications of oligometastatic breast cancer","volume":"30","author":"Jain","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0015","first-page":"988","article-title":"Defining oligoprogression","volume":"30","author":"Greer","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0020","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111789_b0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111789_b0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-008-0157-4","article-title":"Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy","volume":"115","author":"Milano","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111789_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","article-title":"Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer","volume":"26","author":"Scorsetti","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111789_b0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0045","first-page":"337","article-title":"Treatment outcomes of breast cancer patients with bone-only oligometastatic disease treated with stereotactic body radiotherapy","volume":"52","author":"Onal","year":"2018","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111789_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","article-title":"Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade","volume":"131","author":"Milano","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0060","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3389\/fonc.2020.00987","article-title":"Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer","volume":"10","author":"Weykamp","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0065","unstructured":"[Reference to be supplied by the authors \u2014 Li 2020 cohort, 10 patients with visceral oligometastases]."},{"key":"10.1016\/j.radonc.2026.111789_b0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters","volume":"161","author":"Tan","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0075","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1002\/cam4.4068","article-title":"Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer","volume":"10","author":"Wijetunga","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2026.111789_b0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10585-022-10167-6","article-title":"Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients","volume":"39","author":"Nicosia","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2026.111789_b0085","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.clon.2023.08.006","article-title":"Ten-year outcomes of stereotactic body radiotherapy for oligometastatic breast cancer: does synchronous oligometastatic breast cancer benefit?","volume":"35","author":"Nagpal","year":"2023","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110240","article-title":"Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy for medically inoperable lung and liver oligometastases from breast cancer","volume":"195","author":"Franceschini","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12672-024-01595-9","article-title":"Stereotactic body radiotherapy combined with systemic therapy in oligometastatic and oligoprogressive breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0100","article-title":"SABR for oligoprogressive ER-positive breast cancer","volume":"1","author":"Armstrong","year":"2024","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.radonc.2026.111789_b0105","article-title":"Time to next systemic treatment after SABR for oligometastatic breast cancer","volume":"79","author":"Leblanc","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111789_b0110","article-title":"Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer","author":"Milano","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111789_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.103670","article-title":"Stereotactic ablative radiotherapy for bone-only oligometastatic breast cancer: on a quest to find the optimum cohort","volume":"37","author":"Yilmaz","year":"2025","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0120","unstructured":"Sch\u00e4fer R, N\u00e4gler-Guerini A, et al. Stereotactic body radiotherapy for oligometastatic spinal and non-spinal bone metastases from breast cancer: a multicenter European analysis. Clin Transl Radiat Oncol 2026 [Epub ahead of print]."},{"key":"10.1016\/j.radonc.2026.111789_b0125","article-title":"Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor\u2013positive breast cancer (TROG 20.03 AVATAR): a phase II prospective multicenter trial","volume":"2","author":"David","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.radonc.2026.111789_b0130","first-page":"172","article-title":"Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis","volume":"163","author":"Viani","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0135","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care therapy with or without stereotactic body radiotherapy for newly oligometastatic breast cancer","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijrobp.2024.10.030","article-title":"Randomized phase II trial of ablative radiotherapy for oligometastatic breast cancer (EXTEND)","volume":"121","author":"Reddy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111789_b0145","first-page":"1887","article-title":"Stereotactic ablative radiotherapy for patients with oligometastatic breast cancer (CURB): a prospective, randomised, open-label, two-group, phase 2 trial","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111789_b0150","article-title":"Metastases-directed treatment in patients with oligometastatic breast cancer: results from the OLIGOMA trial (ARO-2021-09; NCT04495309)","author":"Krug","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0155","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111789_b0160","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0165","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2026.111789_b0170","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111789_b0175","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111789_b0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.radonc.2026.111789_b0185","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.radonc.2026.111789_b0190","series-title":"An introduction to the bootstrap","author":"Efron","year":"1993"},{"key":"10.1016\/j.radonc.2026.111789_b0195","first-page":"1117","article-title":"6th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 6)","volume":"33","author":"Cardoso","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111789_b0200","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111789_b0205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111789_b0210","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:24:50Z","timestamp":1789914290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S0167814026006298"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111789","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111789"}}